EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project

Ulrich Laufs, Alberico Luigi Catapano, Raffaele De Caterina, François Schiele, Alessandro Sionis, Azfar Zaman, J Wouter Jukema

Vascular Pharmacology · 2023-02 · 148 · 107141

DOI: 10.1016/j.vph.2023.107141 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Vascular Pharmacology, 2023-02. Verfasst von Ulrich Laufs und 6 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany. Electronic address: Ulrich.Laufs@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Anticholesteremic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: To evaluate the effect of the ESC/EAS 2019 dyslipidaemia guidelines on patient management of lipid-lowering therapy in patients with acute coronary syndrome (ACS), through a survey designed to compare post-ACS patient management in 2022 with that in 2018. METHODS: Online questionnaires focused on lipid profile and medications were used to gather data from 2650 ACS patients in 6 European countries, treated between March-June 2022 (ACS EuroPath IV survey). These data were compared with data collected from 2650 patients who participated in the ACS EuroPath I survey (conducted in 2018). RESULTS: Lipid testing was performed in 90% of patients and was done sooner after admission in 2022 versus 2018 (mean 1.4 vs 1.7 days). Increased testing for non-HDL-C, lipoprotein(a), and ApoB was observed over time. At discharge, most patients (≥90%) were receiving lipid-lowering therapy. Prescribing patterns differed, with a higher proportion of patients receiving statin plus ezetimibe combination therapy in 2022 versus 2018 (34% vs 13%). LDL-C levels were lower in 2022 versus 2018 at admission and at 1st, 2nd and 3rd post-discharge follow-up points. More patients achieved low-density lipoprotein cholesterol (LDL-C) goals in 2022 versus 2018 at the first follow-up (average 14 vs 16 weeks since discharge;

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeHydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasAnticholesteremic AgentsHumansCholesterol, LDLGoalsAftercareTreatment OutcomePatient Discharge

Stichwörter der Autor:innen

Acute coronary syndromeDyslipidaemiaGuidelinesLipids

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany. Electronic address: Ulrich.Laufs@medizin.uni-leipzig.de.
  • Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy. Electronic address: alberico.catapano@unimi.it.
  • Chair of Cardiology, University of Pisa; Cardiovascular Division, Pisa University Hospital, Pisa, Italy, and Fondazione Villaserena per la Ricerca, Città Sant'Angelo, Pescara, Italy. Electronic address: raffaele.decater…
  • University Hospital Jean Minjoz, Department of Cardiology, Besançon EA3920, France; University of Burgundy Franche-Comte, Besançon, France. Electronic address: francois.schiele@univ-fcomte.fr.
  • Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029…
  • Cardiology, Freeman Hospital and Newcastle University, Newcastle-upon-Tyne, UK. Electronic address: azfar.zaman@nhs.net.

Förderung

  • Sanofi US

Zitieren

APA

Laufs, U., Catapano, A. L., De Caterina, R., Schiele, F., Sionis, A., Zaman, A., & Jukema, J. W. (2023). The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vascular Pharmacology, 148, 107141. https://doi.org/10.1016/j.vph.2023.107141

Vancouver

Laufs U, Catapano AL, De Caterina R, Schiele F, Sionis A, Zaman A, et al. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vascular Pharmacology. 2023;148:107141. doi:10.1016/j.vph.2023.107141

BibTeX
@article{Laufs2023,
  author = {Laufs, Ulrich and Catapano, Alberico Luigi and De Caterina, Raffaele and Schiele, François and Sionis, Alessandro and Zaman, Azfar and Jukema, J Wouter},
  title = {The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project},
  journal = {Vascular Pharmacology},
  year = {2023},
  volume = {148},
  pages = {107141},
  doi = {10.1016/j.vph.2023.107141}
}
Kostenlos starten →